乳腺癌患者的HSP90α、CA153、CEA、Fer水平变化及临床意义
|
摘要
目的通过联合检测乳腺癌患者血清中的HSP90α、CA153、CEA、Fer水平浓度,提高乳腺癌在临床上的诊效能。方法收集乳腺癌住院患者共85例,乳腺良性肿块患者96例和健康体检者120例。分别检测其血清中的HSP90α、CA153、CEA、Fer水平浓度。结果 HSP90α、CA153、CEA、Fer在乳腺癌组中的水平浓度均高于乳腺良性肿块组和健康对照组,差异具有统计学意义(P<0.05)。健康对照组和乳腺良性肿块组的各指标水平浓度差异没有统计学意义。结论单独检测HSP90α对乳腺癌具有较高的诊断价值。HSP90α、CA153、CEA、Fer联合检测可提高乳腺癌的诊断价值。
Objective To evaluate the clinical value of HSP90α, CA153, CEA and Fer levels in breast cancer by combined detection of serum levels of breast cancer patients. Methods A total of 85 patients with breast cancer in our hospital from January 2016 to March 2017 were collected.There were 96 cases of benign breast tumors and 120 cases of physical examination. The concentrations of HSP90α, CA153, CEA and Fer were detected respectively. Results The levels of HSP90α, CA153, CEA and Fer in breast cancer group were higher than those in breast benign tumor group and healthy control group, the difference was significant(P<0.05). There was no significant difference in the levels of the indexes between the healthy control group and the breast benign tumor group. Conclusion The independent detection of HSP90α alpha is of high diagnostic value for breast cancer. The combined detection of HSP90α, CA153, CEA and Fer can improve the diagnostic value of breast cancer.
Objective To evaluate the clinical value of HSP90α, CA153, CEA and Fer levels in breast cancer by combined detection of serum levels of breast cancer patients. Methods A total of 85 patients with breast cancer in our hospital from January 2016 to March 2017 were collected.There were 96 cases of benign breast tumors and 120 cases of physical examination. The concentrations of HSP90α, CA153, CEA and Fer were detected respectively. Results The levels of HSP90α, CA153, CEA and Fer in breast cancer group were higher than those in breast benign tumor group and healthy control group, the difference was significant(P<0.05). There was no significant difference in the levels of the indexes between the healthy control group and the breast benign tumor group. Conclusion The independent detection of HSP90α alpha is of high diagnostic value for breast cancer. The combined detection of HSP90α, CA153, CEA and Fer can improve the diagnostic value of breast cancer.
引文
[1]李春燕,贺杰,孙冬霞.青年与中老年女性乳腺癌患者的临床特征及生存率比较分析[J].现代中西医结合杂志,2016,25(12):1307-1309.
[2]张燕.乳腺癌患者的城乡差别及化疗依从性的综合护理干预[D].山东大学,2016.
[3]杨荣益.农村女性乳腺癌患者就医行为研究[D].云南大学,2016.
[4]孙小涵,曹勤,肖建英.血清肿瘤标志物和细胞因子在乳腺癌检测中的临床意义研究[J].海南医学院学报,2017,23(2):197-200.
[5]谢军花.肿瘤标志物检测在恶性肿瘤诊断中的价值与应用[J].国际检验医学杂志,2017,38(8):1123-1125.
[6]马玉,马雅静,李旭哲,等.健康体检人群肿瘤标志物的异常状态:分子水平肿瘤早期筛查的临床意义[J].临床与实验病理学杂志,2017,33(1):12-17.
[7]申绯翡,李姣锋,吕会茹,等.新兴肿瘤标志物及其临床应用的研究进展[J].国际检验医学杂志,2016,37(20):2870-2873.
[8]张闻龙,卢仁泉,江铭磊,等.血浆热休克蛋白90α在乳腺癌诊疗中的应用价值[J].检验医学,2017,32(5):374-377.
[9]营巧玲,李前文,杜云翔.热休克蛋白90α在肿瘤、食管癌中的研究[J].现代肿瘤医学,2015,23(12):1750-1752.
[10]黄琳.牙鲆免疫相关基因及热休克蛋白基因的转录表达[D].中国科学院研究生院(海洋研究所),2015.
[11]鲁薪安.底物激酶调控热休克蛋白90α分子伴侣功能的机理研究[D].清华大学,2015.
[12]罗永章.血浆Hsp90α是一个全新的肿瘤标志物[A]//中国医师协会肿瘤医师分会、中国抗癌协会肿瘤临床化疗专业委员会.中国肿瘤内科进展中国肿瘤医师教育(2014)[C].中国医师协会肿瘤医师分会、中国抗癌协会肿瘤临床化疗专业委员会,2014:3.
[13]顾淑霞,刘蔚如,付彦.罗永章团队在国际上首次证明新肿瘤标志物Hsp90α[N].新清华,2013-11-22001.
[14]Yuan-Kai Shi,Xiao-Qing Liu,Jia-Tao Lou,et al.A new biomarker heat-shock protein 90 alpha as therapeutic monitor and predictor for lung cancer patients[A]//Asian and Pacific Federation of Organizations for Cancer Research and Control(APFOCC),Chinese Anti-Cancer Association(CACA),Tianjin Medical University Cancer Institute&Hospital(TMUCIH).Proceedings of the 22nd Asia Pacific Cancer Conference[C].Asian and Pacific Federation of Organizations for Cancer Research and Control(APFOCC),Chinese Anti-Cancer Association(CACA),Tianjin Medical University Cancer Institute&Hospital.
[15]贺丽亚,房保栓,邱刚,等.NSCLC组织中Hsp90α的表达及其临床意义[J].河北医学,2014,20(5):717-720.
[16]Wang J,Cui S,Zhang X,et al.High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric can-cer[J].PLo S One,2013,8(4):e62876.
[17]陶健,胡明泰,周明,等.乳腺癌外周血乳腺上皮小黏蛋白和CA153联合检测的临床价值[J].中国肿瘤临床与康复,2017,24(3):266-269.
[18]皮亚平,田柳.肿瘤标志物CA153、CA125联合检查对乳腺癌诊断的价值分析[J].实用癌症杂志,2017,32(8):1351-1353.
[19]张立刚.免疫指标检测用于乳腺癌患者中的临床效果[J].世界最新医学信息文摘,2017(65):189-191.
[20]登峰.体质指数与乳腺癌发生发展及预后因素关系的探讨[D].吉林大学,2016.
[21]南永刚,刘新芸,施常备,等.血清CA153和HER-2联合检测在乳腺癌诊断中的研究[J].标记免疫分析与临床,2016,23(7):731-733.
[22]王芳,孙素青,李朝霞,等.超声弹性成像联合血清CA153检测在乳腺癌诊断中的价值[J].临床合理用药杂志,2016,9(14):120-121.
[23]张琼霞,王希成,陈树鹏,等.干细胞标志物ALDH1与大样本乳腺癌患者的预后关系[J].临床医学工程,2016,23(12):1585-1587.
[24]刘淳,林顺欢,郑锐年,等.乳腺癌患者血清CEA、Ki67及HIF-1α水平与临床病理参数的相关性[J].中国肿瘤临床与康复,2017,24(8):960-963.
[25]蔡兆根,张琼,于东红,等.乳腺分泌性癌8例临床病理分析[J].中国组织化学与细胞化学杂志,2017,26(2):165-169,177.
[26]吴立春,谷仕艳,代黄梅,等.长链非编码RNA-ROR在乳腺癌患者血清、癌组织中的表达变化及其临床意义[J].山东医药,2017,57(32):78-80.
[27]曾素丹,秦超,梁志坚,等.乳腺癌手术围术期脑梗死患者的临床特点分析[J].广西医科大学学报,2015,32(6):917-920.
[28]曹加伟,黄梅,严晶,等.针刺对DMBA诱导的乳腺癌大鼠ER、PR表达的影响[J].上海针灸杂志,2016,35(3):344-348.
[29]蔡学敏,朱向情,沈丽蓉,等.DC-CTL免疫细胞抗肿瘤治疗疗效观察[A]//中国实验动物学会.第十二届中国实验动物科学年会(2016·南宁)论文集[C].中国实验动物学会,2016.
[30]魏文青.铁蛋白与肿瘤的发生发展[J].中国热带医学,2014,14(1):125-127,130.
[31]张美玲,董恒进.乳腺癌基因分型与血清肿瘤标志物表达的相关性分析[J].中国现代应用药学,2017,34(1):111-115.
[2]张燕.乳腺癌患者的城乡差别及化疗依从性的综合护理干预[D].山东大学,2016.
[3]杨荣益.农村女性乳腺癌患者就医行为研究[D].云南大学,2016.
[4]孙小涵,曹勤,肖建英.血清肿瘤标志物和细胞因子在乳腺癌检测中的临床意义研究[J].海南医学院学报,2017,23(2):197-200.
[5]谢军花.肿瘤标志物检测在恶性肿瘤诊断中的价值与应用[J].国际检验医学杂志,2017,38(8):1123-1125.
[6]马玉,马雅静,李旭哲,等.健康体检人群肿瘤标志物的异常状态:分子水平肿瘤早期筛查的临床意义[J].临床与实验病理学杂志,2017,33(1):12-17.
[7]申绯翡,李姣锋,吕会茹,等.新兴肿瘤标志物及其临床应用的研究进展[J].国际检验医学杂志,2016,37(20):2870-2873.
[8]张闻龙,卢仁泉,江铭磊,等.血浆热休克蛋白90α在乳腺癌诊疗中的应用价值[J].检验医学,2017,32(5):374-377.
[9]营巧玲,李前文,杜云翔.热休克蛋白90α在肿瘤、食管癌中的研究[J].现代肿瘤医学,2015,23(12):1750-1752.
[10]黄琳.牙鲆免疫相关基因及热休克蛋白基因的转录表达[D].中国科学院研究生院(海洋研究所),2015.
[11]鲁薪安.底物激酶调控热休克蛋白90α分子伴侣功能的机理研究[D].清华大学,2015.
[12]罗永章.血浆Hsp90α是一个全新的肿瘤标志物[A]//中国医师协会肿瘤医师分会、中国抗癌协会肿瘤临床化疗专业委员会.中国肿瘤内科进展中国肿瘤医师教育(2014)[C].中国医师协会肿瘤医师分会、中国抗癌协会肿瘤临床化疗专业委员会,2014:3.
[13]顾淑霞,刘蔚如,付彦.罗永章团队在国际上首次证明新肿瘤标志物Hsp90α[N].新清华,2013-11-22001.
[14]Yuan-Kai Shi,Xiao-Qing Liu,Jia-Tao Lou,et al.A new biomarker heat-shock protein 90 alpha as therapeutic monitor and predictor for lung cancer patients[A]//Asian and Pacific Federation of Organizations for Cancer Research and Control(APFOCC),Chinese Anti-Cancer Association(CACA),Tianjin Medical University Cancer Institute&Hospital(TMUCIH).Proceedings of the 22nd Asia Pacific Cancer Conference[C].Asian and Pacific Federation of Organizations for Cancer Research and Control(APFOCC),Chinese Anti-Cancer Association(CACA),Tianjin Medical University Cancer Institute&Hospital.
[15]贺丽亚,房保栓,邱刚,等.NSCLC组织中Hsp90α的表达及其临床意义[J].河北医学,2014,20(5):717-720.
[16]Wang J,Cui S,Zhang X,et al.High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric can-cer[J].PLo S One,2013,8(4):e62876.
[17]陶健,胡明泰,周明,等.乳腺癌外周血乳腺上皮小黏蛋白和CA153联合检测的临床价值[J].中国肿瘤临床与康复,2017,24(3):266-269.
[18]皮亚平,田柳.肿瘤标志物CA153、CA125联合检查对乳腺癌诊断的价值分析[J].实用癌症杂志,2017,32(8):1351-1353.
[19]张立刚.免疫指标检测用于乳腺癌患者中的临床效果[J].世界最新医学信息文摘,2017(65):189-191.
[20]登峰.体质指数与乳腺癌发生发展及预后因素关系的探讨[D].吉林大学,2016.
[21]南永刚,刘新芸,施常备,等.血清CA153和HER-2联合检测在乳腺癌诊断中的研究[J].标记免疫分析与临床,2016,23(7):731-733.
[22]王芳,孙素青,李朝霞,等.超声弹性成像联合血清CA153检测在乳腺癌诊断中的价值[J].临床合理用药杂志,2016,9(14):120-121.
[23]张琼霞,王希成,陈树鹏,等.干细胞标志物ALDH1与大样本乳腺癌患者的预后关系[J].临床医学工程,2016,23(12):1585-1587.
[24]刘淳,林顺欢,郑锐年,等.乳腺癌患者血清CEA、Ki67及HIF-1α水平与临床病理参数的相关性[J].中国肿瘤临床与康复,2017,24(8):960-963.
[25]蔡兆根,张琼,于东红,等.乳腺分泌性癌8例临床病理分析[J].中国组织化学与细胞化学杂志,2017,26(2):165-169,177.
[26]吴立春,谷仕艳,代黄梅,等.长链非编码RNA-ROR在乳腺癌患者血清、癌组织中的表达变化及其临床意义[J].山东医药,2017,57(32):78-80.
[27]曾素丹,秦超,梁志坚,等.乳腺癌手术围术期脑梗死患者的临床特点分析[J].广西医科大学学报,2015,32(6):917-920.
[28]曹加伟,黄梅,严晶,等.针刺对DMBA诱导的乳腺癌大鼠ER、PR表达的影响[J].上海针灸杂志,2016,35(3):344-348.
[29]蔡学敏,朱向情,沈丽蓉,等.DC-CTL免疫细胞抗肿瘤治疗疗效观察[A]//中国实验动物学会.第十二届中国实验动物科学年会(2016·南宁)论文集[C].中国实验动物学会,2016.
[30]魏文青.铁蛋白与肿瘤的发生发展[J].中国热带医学,2014,14(1):125-127,130.
[31]张美玲,董恒进.乳腺癌基因分型与血清肿瘤标志物表达的相关性分析[J].中国现代应用药学,2017,34(1):111-115.